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Background: Ready-to-use therapeutic foods (RUTF) are lipid-based pastes widely used in the treatment of acute
malnutrition. Current specifications for RUTF permit a high n-6 polyunsaturated fatty acid (PUFA) content and low
n-3 PUFA, with no stipulated requirements for preformed long-chain n-3 PUFA. The objective of this study was to
develop an RUTF with elevated short-chain n-3 PUFA and measure its impact, with and without fish oil supplementation,
on children’s PUFA status during treatment of severe acute malnutrition.
Methods: This randomized controlled trial in children with severe acute malnutrition in rural Kenya included 60 children
aged 6 to 50 months who were randomized to receive i) RUTF with standard composition; ii) RUTF with elevated short
chain n-3 PUFA; or iii) RUTF with elevated short chain n-3 PUFA plus fish oil capsules. Participants were followed-up for
3 months. The primary outcome was erythrocyte PUFA composition.
Results: Erythrocyte docosahexaenoic acid (DHA) content declined from baseline in the two arms not receiving fish oil.
Erythrocyte long-chain n-3 PUFA content following treatment was significantly higher for participants in the arm receiving
fish oil than for those in the arms receiving RUTF with elevated short chain n-3 PUFA or standard RUTF alone: 3 months
after enrolment, DHA content was 6.3% (interquartile range 6.0–7.3), 4.5% (3.9–4.9), and 3.9% (2.4–5.7) of total erythrocyte
fatty acids (P <0.001), respectively, while eicosapentaenoic acid (EPA) content was 2.0% (1.5–2.6), 0.7% (0.6–0.8), and 0.4%
(0.3–0.5) (P <0.001). RUTF with elevated short chain n-3 PUFA and fish oil capsules were acceptable to participants and
carers, and there were no significant differences in safety outcomes.
Conclusions: PUFA requirements of children with SAM are not met by current formulations of RUTF, or by an RUTF with
elevated short-chain n-3 PUFA without additional preformed long-chain n-3 PUFA. Clinical and growth implications of
revised formulations need to be addressed in large clinical trials.
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Severe acute malnutrition (SAM) is a major risk factor for
morbidity and mortality in early childhood. SAM com-
prises two distinct clinical syndromes, severe wasting (diag-
nosed on the basis of weight-for-height or mid-upper arm
circumference (MUAC)) and kwashiorkor (edematous
malnutrition). The global prevalence of severe wasting in
children less than 5 years of age is 2.9% and, whilst the glo-
bal burden of kwashiorkor is undefined, in some settings it
contributes up to 50% of SAM cases [1,2]. Both syndromes
are associated with greatly increased mortality from com-
mon infectious diseases such as pneumonia and diarrhea
via mechanisms that are not fully understood [3,4]. Severe
wasting alone underlies 7.4% of global deaths in children
under five (approximately 500,000 deaths each year), and
kwashiorkor is associated with a high mortality rate [1,5].
The clinical management of SAM involves a series of
interventions designed to treat, ameliorate, or minimize
metabolic disturbance and complications during nutri-
tional rehabilitation. The current paradigm comprises an
integrated system where inpatient care is reserved for
those children who have medical complications or poor
appetite, and outpatient care is provided to those who are
medically stable and have appetite [6]. A key enabling fac-
tor in the implementation of community management of
acute malnutrition has been the development of lipid-
based ready-to-use therapeutic foods (RUTF), which aim
to provide a nutritionally complete diet for rehabilitation
of SAM. RUTF are microbiologically stable by virtue of
their low water activity, making them suitable for use at
home. The technical specification for nutritional compos-
ition of RUTF is almost identical to that for ‘F-100’ thera-
peutic milk, which is the standard of care for inpatient
nutritional rehabilitation of children with SAM and was
based, for the most part, on published specifications for
infant formula manufacture [7]. There have been no major
changes to the compositional specifications of F-100 or
RUTF since they were originally designed [8].
The n-6 (omega-6) and n-3 (omega-3) families of poly-
unsaturated fatty acids (PUFA) are biologically important
molecules with a wide variety of structural and func-
tional roles. They are immunologically active, as precur-
sors to the eicosanoid family of inflammatory mediators
and as a result of their characteristic physical properties
when incorporated in the lipid membranes of immune
cells [9], and affect a number of risk factors for cardio-
vascular disease. The n-3 long-chain (LC)-PUFA docosa-
hexaenoic acid (DHA, 22:6(n-3)) and n-6 LC-PUFA
arachidonic acid (AA, 20:4(n-6)) have key structural and
functional roles in the eye and brain and are thus im-
portant in early life development of these organs [10].
The short chain n-6 PUFA linoleic acid (LA, 18:2(n-6)),
and the short chain n-3 PUFA alpha-linoleic acid (ALA,
18:3(n-3)) cannot be synthesized de novo and must beprovided by dietary intake. They act as precursors for the
biosynthesis of n-6 and n-3 LC-PUFA, which are pro-
duced by the sequential action of desaturase and elongase
enzymes. Nevertheless, LC-PUFA may also be consumed
preformed in the diet.
Specifications for F-100 and RUTF permit broad ranges
of PUFA composition, with n-6 and n-3 fatty acids com-
prising 3 to 10% and 0.3 to 2.5% of total energy, respect-
ively. There is no stipulation for provision of preformed
LC-PUFA. LA is abundant in peanuts and many of the
vegetable oils normally used in manufacturing RUTF but
ALA is present at high concentration in a limited range of
vegetable oils. LC-PUFA are absent from vegetable sources,
meaning that RUTF prepared with only vegetable-derived
lipid has low absolute n-3 PUFA and no n-3 LC-PUFA.
Flax seed oil is a good source of ALA while fish oil is a
good source of n-3 LC-PUFA.
The objectives of this trial were to determine whether a
formulation of RUTF with elevated short chain n-3 PUFA
(ALA) content is practical, safe, and acceptable in the
management of children with SAM; and whether its use
has an impact on children’s PUFA status, and in particular
LC-PUFA status, as measured by erythrocyte fatty acid
composition. In order to determine an absolute require-
ment for preformed n-3 LC-PUFA, the new formulation
was tested with or without fish oil supplementation in
addition to RUTF. Because LC-PUFA are immunologically
active, secondary objectives included assessment for
impact on PUFA composition and function of T cells.
Methods
This was a single center, three-armed randomized con-
trolled trial with balanced randomization (1:1:1). Severely
acutely malnourished Kenyan children received nutritional
rehabilitation with a standard RUTF (S-RUTF); a flax seed
oil-containing RUTF (F-RUTF); or flax seed oil-containing
RUTF with additional fish oil capsules (FFO-RUTF). Flax
seed oil provides ALA while fish oil capsules provide the
n-3 LC-PUFA eicosapentaenoic acid (EPA; 20:5(n-3)) and
DHA. The trial was conducted double-blind between the
S-RUTF and F-RUTF arms and open label with respect to
FFO-RUTF.
Participants and setting
The study took place between June 2012 and July 2013
at Kilifi County Hospital (KCH) in coastal Kenya. Kilifi
County comprises a mostly rural subsistence-farming
community and at least 60% of residents live below the
national poverty line [11]. KCH is a government referral
facility with more than 5,000 pediatric admissions per
year to either a 54-bed ward or 10-bed high dependency
unit where clinical care is supported by staff and funding
from the Kenya Medical Research Institute (KEMRI)-
Wellcome Trust Research Programme. Children with
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tritional and medical management is provided. Uncompli-
cated SAM cases are managed at KCH’s on-site outpatient
therapeutic feeding program (OTP).
All children admitted to hospital and those presenting
to the OTP were screened for potential eligibility. Par-
ticipants were aged 6 to 60 months with SAM defined
as either MUAC <11.5 cm, weight-for-height/length
z-score < −3, or bilateral pedal edema (kwashiorkor),
had been medically and nutritionally stabilized, and were
eligible to receive RUTF according to national guidelines.
Children were excluded if they were HIV-infected, under-
going treatment for tuberculosis, had other recognized or
suspected major chronic inflammatory conditions (e.g.,
malignancy), or reported allergy or hypersensitivity to
any of the product ingredients.
Intervention
We used linear programming analysis to design a novel
RUTF with increased ALA content. The RUTF was based
on a standard formulation produced by Valid Nutrition
(Lilongwe, Malawi) with the addition of cold-pressed flax
seed oil purchased from Seed Oil SA (Somerset West,
South Africa). Gas chromatographic analysis of the final
recipe (performed as described later) showed that n-3
PUFA comprised 3.3% of total energy content, compared
to 0.7% in the standard formulation (similar to that found
in Plumpy’nut, the most widely available brand of RUTF;
Additional file 1: Table S1), and n-6 PUFA comprised
7.9% of total energy compared to 8.2% in the standard.
Both the standard formulation and the flax seed oil-
containing RUTFs were packaged in identical 92 g sachets
under nitrogen and stored below 25°C for the duration of
the study. The two recipes were organoleptically indistin-
guishable. Neither recipe contained any preformed n-3
LC-PUFA. Peroxidation of the RUTF was assessed by
iodometric endpoint determination (ISO 3960: 2007).
Standard or flax seed oil-containing RUTF was provided
to children at a dose determined by weight according to
national guidelines until MUAC was >11.5 cm, weight-
for-height/length z-score > −3, or edema had resolved
(depending on enrolment criteria) at two consecutive
weekly visits. Parents were advised that no other food-
stuff should be consumed during treatment of SAM
apart from breast milk. Thereafter, RUTF was provided
for use in a supplementary fashion alongside family
foods at 50% of the recommended daily therapeutic
dose until completion of the study, 84 days after enrol-
ment. RUTF has been safely used in a supplementary
fashion before and the recommended compositions of
therapeutic and supplementary lipid-based nutritional
supplements are similar [8,12]. The dose provided dur-
ing the supplementary phase was often higher than rec-
ommended in national guidelines, which stipulate one92 g sachet per day regardless of body weight. However,
provision of markedly different per-kg body weight doses
during the study would have introduced additional
variation of intake in relation to needs and would have
decreased the power of the study.
Children enrolled to the third arm of the trial were
provided with two 0.5 mL fish oil capsules donated for
use in the study by Seven Seas (Hull, UK), providing
214 mg of EPA plus DHA at a ratio of 1.7:1.0 (with 4
International Units vitamin E), for each 92 g sachet of
(flax seed oil-containing) RUTF prescribed. Carers were
instructed to pierce the capsules with a safety pin and
squeeze the oil into the child’s mouth. This is the same
technique used to deliver vitamin A to young children
and was familiar and acceptable to participants. We cal-
culated that participants in this arm would effectively re-
ceive 3.9% of total energy as n-3 PUFA, 16% of which
would be as preformed EPA and DHA (0.39% and 0.22%
total energy, respectively), compared to a DHA recom-
mended intake for healthy infants of 0.10 to 0.18% [13].
This is likely to be an overestimate since piercing the
capsule and squeezing it into the participant’s mouth
was likely to preclude delivery of the entire contents.Study procedures
Information about the study was given to each eligible
child’s attending parent or carer as soon as possible after
presentation and informed consent for participation was
sought. Where consent was provided, children were
reviewed by a member of the study team daily, until the
clinical attending team considered them medically stabi-
lized and ready to start RUTF. At this point they were
formally enrolled in the trial, given a study number (see
below), and started on blinded standard or flax seed oil-
containing RUTF with or without fish oil capsules ac-
cording to the allocation arm. Participants who required
ongoing inpatient care were reviewed by a member of
the study team daily until discharge. Scheduled study
follow-up took place at days 7, 14, 21, 28, 56, and 84
after enrolment. RUTF and capsules were provided at
each visit. Capsules were provided in an amber plastic
bottle and were dispensed by weight. Compliance was
monitored by interview with the parent or carer, count-
ing full and empty sachets of RUTF and by reweighing
the returned bottles containing fish oil capsules. Percent-
age compliance was calculated with reference to a ‘full ra-
tion’ taking account of the participant’s weight and stage
of treatment. During therapeutic feeding, additional RUTF
was offered to be used after completion of the full pre-
scribed ration if children were still hungry, in line with na-
tional guidelines. Blood samples were taken at enrolment
and at days 7, 28, and 84. Monitoring for side effects or
adverse events was conducted at all scheduled and
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and defaulters were traced in the community.
Outcomes
The primary outcome was erythrocyte n-3 PUFA content
(percentage of the major species and n-6:n-3 PUFA con-
tent ratio) at day 84 measured by gas chromatography.
Main secondary outcomes were safety and acceptability of
the intervention, assessed by frequency of adverse events
and compliance, respectively. The study was not powered
or designed to detect differences in rate of recovery or
growth, but these data were collected and are reported. A
large number of other outcomes were measured in order
to provide mechanistic insights relevant to future study
design. Further analysis of fatty acid abundance in plasma
phosphatidylcholine (at enrolment, and days 28 and 84)
and T cells (at enrolment and day 84) was performed; in-
flammatory activation was assessed by measurement of a
range of soluble mediators in plasma; insulin-like growth
factor-1 (IGF-1) provided an index of linear growth poten-
tial; in vivo T cell activation/exhaustion and in vitro re-
sponse to stimulation with mitogen and recall antigen
were measured at enrolment and day 84; and biophysical
properties of the erythrocyte membrane were assessed by
response to shear stress. These outcomes were considered
exploratory.
Sample size, randomization, and blinding
Sample size was calculated with reference to changes over
time in erythrocyte membrane fatty acids amongst a group
of Thai schoolchildren provided with n-3 LC-PUFA-
fortified milk for 6 months [14]. DHA composition of
total erythrocyte fatty acids increased by 3.6% (standard
deviation 1.5). We calculated the sample size based on an
effect size 50% of this magnitude (because the duration of
follow-up was only half as long), which came to 15 in each
group. Allowing for up to 25% failure to complete the trial
due to mortality or drop-out gave a final size of 20
children per arm, or 60 overall.
Standard and flax seed oil-containing RUTF were pro-
duced by Valid Nutrition (Lilongwe, Malawi). Each sachet
was stamped with one of 18 indelible four-digit alpha-
numeric codes; 6 of the codes were designated to the stand-
ard recipe, and 12 to the flax seed oil-containing recipe (6
each for the arms with and without fish oil capsules). Access
to the allocation key was restricted to manufacturers and
the trial statistician (GF). A randomization list was generated
in STATA (version 12.0) with variable block sizes using the
following code: “ralloc blknum blksiz Rx, nsubj(60) ntreat
(3)” [15]. The trial statistician prepared 60 opaque envelopes
labeled with study numbers, inside each of which was a card
identifying a four-digit RUTF code and specifying ‘with fish
oil’ or ‘without fish oil’. When a participant was enrolled in
the trial they were allocated the next consecutively availablestudy number, which was entered on the allocation log prior
to opening the relevant envelope.
Because of difficulties sourcing an appropriate placebo oil
capsule, the FFO-RUTF arm was open label with respect to
both the provision of fish oil capsules and flax seed oil-
containing RUTF.Laboratory methods
Separation of blood components for analysis of fatty acid
composition
Whole blood was collected into sodium heparin vacutai-
ners (BD, Franklin Lakes, New Jersey, USA). Plasma and
leukocyte fractions were isolated by separation over a
discontinuous density gradient created by layering Histo-
paque 1077 on top of Histopaque 1119 (Sigma-Aldrich
Limited, Gillingham, UK). After centrifugation at 700 g
for 30 minutes, peripheral blood mononuclear cells were
reserved, plasma was stored directly at −80°C, and the
red cell pellet (free of granulocyte contamination) was
washed twice in phosphate buffered saline and stored at
−80°C. CD3+ T cells were isolated from peripheral blood
mononuclear cells by positive selection using CD3
MicroBeads and LS columns (Miltenyi Biotec, Bergisch
Gladbach, Germany) according to the manufacturer’s
instructions, and also stored at −80°C.Lipidomic analysis
Total lipid was extracted from the stored samples ac-
cording to the method of Bligh & Dyer with dichlorometh-
ane replacing chloroform, and dried under nitrogen [16].
Plasma phosphatidylcholine was isolated using solid phase
extraction on aminopropylsilica cartridges (Agilent Tech-
nologies, Santa Clara, USA). For fatty acid analysis (erythro-
cyte and plasma phosphatidylcholine samples), methyl
esters were generated by incubation with methanol con-
taining 2% H2SO4 and extracted into hexane following
neutralization as described previously [17]. Analysis was
performed on a Hewlett Packard 6890 gas chromatograph
fitted with a BPX-70 column. Fatty acid methyl esters were
identified using HPChemStation (Hewlett Packard, Palo
Alto, USA) by retention time compared to authentic stan-
dards. For whole lipid analysis (CD3+ cells), samples
were reconstituted in dichloromethane:methanol:water:
concentrated ammonia (66:30:3:1) and introduced via
direct infusion by nanoflow electrospray ionization to a
triple quadrupole mass spectrometer (xevo-TQ, Waters,
Milford, USA) [18]. Phosphatidylcholine was analyzed
in positive ionization as precursors of 184+, and phos-
phatidylethanolamine was analyzed in the neutral loss
of 141+. Individual spectra were checked in MassLynx
(Waters, Milford, USA) for quality and analyzed using a
custom-designed macro [19].
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T cell activation phenotypes (CD3+, CD4/8+, CD38+,
HLA-DR+ with/without PD-1 expression) were evaluated
by flow cytometric analysis of fresh whole blood following
staining with appropriate antibodies, and whole blood
interferon gamma (IFN-γ) release in response to phyto-
hemagglutinin (PHA) or tetanus toxoid (TT) with or with-
out IL-12 was quantified (for further details see Additional
file 1: Methods).
Other methods
Full blood count was performed by the Good Clinical and
Laboratory Practice-compliant clinical laboratories at the
KEMRI-Wellcome Trust Research Programme, Kenya.
Erythrocyte deformability in response to shear stress
was measured on-site using a laser-assisted optical rota-
tion analyzer as described previously [20]. Soluble inflam-
matory mediators were measured in plasma (Additional
file 1: Methods).
Statistical methods
All data were double entered and validated with Open-
clinica (Isovera, Waltham, USA). Analysis was performed
in STATA (version 12.0) and anthropometric Z-scores
were calculated using World Health Organization Child
Growth Standards, 2006 [21]. All analyses were done by
the intention-to-treat principle. For compositional out-
comes, comprising key individual molecular species,
calculated total n-6 PUFA and n-3 PUFA content, and
n-6:n-3 ratios, analysis of variance (ANOVA) models
were used to test differences between the three arms at
each time point, and Mann–Whitney U-tests to identify
within-arm changes from baseline. Compliance was cal-
culated and compared between arms using ANOVA.
For grouped variables (e.g., adverse events), significance
was calculated using Fisher’s exact test, or χ2 test where
the expected number in all cells was >5. Changes in an-
thropometric indices were calculated for individual par-
ticipants and compared between groups using ANOVA.
Where indicated in the text, S-RUTF and F-RUTF arms
were considered together as both not containing fish
oil, and F-RUTF and FFO-RUTF were considered together
as both containing flax seed oil. We performed a post hoc
analysis to assess for impact of baseline erythrocyte fatty
acid composition on changes in erythrocyte membrane
composition over the trial using linear regression and
assessing for effect modification on the regression coeffi-
cient by arm. ‘Long-chain’ is used to indicate 20-carbon or
longer chain fatty acids throughout.
Study oversight
All participants enrolled in the study had individual writ-
ten informed consent provided by a parent or guardian.
The study was approved by the KEMRI Ethical ReviewCommittee and the Oxford Tropical Research Ethics
Committee prior to initiation. The University of Oxford
was the sponsor. Clinical trials monitoring was performed
by staff from the Clinical Trials Facility at the KEMRI-
Wellcome Trust Research Programme. An independent
trial steering committee acted as the decision-making
body for the study and an independent pediatrician acted
as local safety monitor. Neither the sponsor nor any other
party except the named investigators had any role in the
design of the study, interpretation of the results, content
of manuscripts, or decision to publish. The trial was regis-
tered at https://clinicaltrials.gov/ct2/show/NCT01593969.
Results
Between May 30, 2012, and April 30, 2013, 236 children
admitted to, or attending, the OTP and inpatient malnu-
trition bay at KCH were assessed for eligibility; 61 children
were enrolled in the trial, one of whom was withdrawn as
ineligible (suspected hematological malignancy) within
24 hours of enrolment and is not included in any of the
analyses (Figure 1).
Stability of the RUTF
Twelve months after manufacture (May 9, 2012) of the
two batches of RUTF we performed a precautionary re-
analysis of the lipid composition of the flax seed oil-
containing formulation to check for deterioration. Al-
though fatty acid composition (by gas chromatography)
and organoleptic qualities were unchanged, on April 18,
2013, the peroxide content of the flax seed oil-containing
product was 17.9 meq/kg, which is higher than the value
stipulated by UNICEF as acceptable for newly manufac-
tured batches (<10 meq/kg). Because deterioration of
RUTF can occur rapidly once peroxidation begins, we
began regular checks on palatability and peroxide levels.
On May 16, 2013, the peroxide levels had risen to
33.5 meq/kg, and investigators considered the flax seed
oil-containing product had become less palatable (despite
the fact that peroxide levels were 29.7 meq/kg in the
standard formulation, it remained palatable). In discussion
with the independent trial steering committee, provision of
all study RUTF and capsules was stopped. Children who
still required therapeutic or supplementary feeds were
switched over to the hospital’s standard supply. Six chil-
dren were affected, 2 in each arm. There were no adverse
events considered attributable to the deterioration and
these 6 participants were included in intention-to-treat
analyses.
Baseline characteristics
The arms were comparable at baseline. Children allocated
to FFO-RUTF tended to have lower MUAC (P = 0.08) and
were less likely to have diarrhea at presentation (P = 0.12)
(Table 1). There were no major differences in baseline
Figure 1 Trial flow diagram.
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or any of the inflammatory or hematological indices.
Follow-up and compliance
Seven children were voluntarily withdrawn at parental re-
quest: 1 in the S-RUTF arm (at day 84), 5 in the F-RUTF
arm (4 before day 7, 1 at day 28), and 1 in the FFO-RUTF
arm (at day 42; P = 0.41 between both elevated n-3 PUFA
(F-RUTF and FFO-RUTF) and the standard RUTF arms).
Compliance with RUTF feeding and capsules amongst chil-
dren still in follow-up was high in all three arms (Table 2).
Safety
Six children (10%) died during follow-up; 5 of these deaths
were associated with severe pneumonia and 1 occurred in
the community where we were unable to ascertain cause of
death. One death occurred in the S-RUTF arm, 3 in the F-
RUTF, and 2 in the FFO-RUTF arms. There were a further
9 severe adverse events (requiring hospitalization or
prolonging hospital stay): 4 were lower respiratory tract
infection (2 in S-RUTF, 2 in FFO-RUTF), 4 were diarrhea/
dehydration (3 in S-RUTF, 1 in FFO-RUTF), and 1 was se-
vere malaria (FFO-RUTF). There were no adverse events
considered directly attributable to the investigational
products.
Non-severe episodes of illness or infection were common
during follow-up, as expected in this high-risk population.Total number of illness episodes and the nature of the epi-
sodes were similar between the groups (Table 2). There was
a greater number of upper respiratory tract infections and
of vomiting episodes reported amongst children receiving
the RUTF with elevated n-3 PUFA (F-RUTF and FFO-
RUTF arms), but neither of these effects were statistically
significant.
Lipidomic analysis
Erythrocytes
There were large and highly significant differences in
erythrocyte membrane fatty acid composition between
the groups at days 28 and 84 (Figure 2 and Additional
file 1: Table S2). The percentage of PUFA increased at
the expense of saturated fatty acids, but there were wide
differences in the behavior of individual species. In the
S-RUTF arm there were increases in n-6 PUFA family
members dihomo-gamma-linolenic acid (20:3(n-6)) and
AA, and also in EPA, but DHA declined significantly
during follow-up. Although breastfeeding was an im-
portant determinant of baseline DHA status, the decline
in DHA occurred in both breastfed and non-breastfed
children (Additional file 1: Figure S1). In the FFO-RUTF
arm, there were marked increases in most of the n-3 LC-
PUFA species (except eicosatetraenoic acid (20:4(n-3))),
while n-6 PUFA family members were unchanged from
baseline. Compared to the other two arms, erythrocyte
Table 1 Baseline characteristics of the participants
Baseline characteristics S-RUTF F-RUTF FFO-RUTF
Participantsa 20 20 20
Age, months 18 (9 to 30) 16 (11 to 25) 14 (11 to 21)
Sex: Male 12 (60) 10 (50) 11 (55)
Nutritional Status
Mid-upper arm circumference, cm 11.2 (10.9 to 11.4) 11.3 (10.8 to 11.9) 10.9 (10.4 to 11.4)
Weight-for-height/length z score −3.11 (−4.43 to −1.89) −3.31 (−3.88 to −2.90) −3.65 (−4.12 to −3.19)
Bilateral pedal edema (kwashiorkor) 1 (5) 1 (5) 0 (0)
Height-for-age z score −3.11 (−3.90 to −1.93) −3.36 (−4.58 to −2.55) −2.58 (−4.20 to −1.97)
Head circumference-for-age z score −1.38 (−3.36 to −0.62) −1.85 (−2.82 to −1.02) −1.37 (−2.27 to −0.56)
Breastfeeding 8 (40) 8 (40) 12 (60)
Complementary feeds introduced, months of age 5 (2 to 6) 4 (2 to 6) 4 (3 to 6)
Complications
Diarrhea 11 (55) 8 (40) 4 (20)
Pneumonia 3 (15) 3 (15) 1 (5)
Shock 1 (5) 2 (10) 0 (0)
Congenital heart disease 3 (15) 1 (5) 3 (15)
Cerebral palsy 3 (15) 1 (5) 4 (20)
Demographics
Main carer is not the mother 4 (20) 5 (25) 1 (5)
Main carer has no primary education 7 (35) 8 (40) 8 (40)
Lives in mud-walled house 13 (65) 15 (75) 17 (85)
No toilet in house/compound 8 (40) 6 (30) 5 (25)
Fisherman in household 1 (5) 2 (10) 2 (10)
Data are number (%) or median (inter-quartile range) unless otherwise specified.
aExcluding one child withdrawn due to ineligibility (S-RUTF arm).
S-RUTF, Trial arm receiving standard-formulation RUTF without fish oil capsules; FFO-RUTF, Trial arm receiving flax seed oil-containing RUTF and fish oil capsules;
F-RUTF, Trial arm receiving flax seed oil-containing RUTF without fish oil capsules.
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modest increases in EPA and a decline in DHA similar to
that seen in S-RUTF.
Alteration in the LC-PUFA species lay behind significant
changes in the overall erythrocyte n-6:n-3 PUFA ratio, but
despite the provision of diets with dramatically different
LA and ALA content there was no difference in the LA:
ALA ratio between the groups at any timepoint, and no
change from baseline.
Ratios of 20:4(n-6)/20:3(n-6), 18:3(n-6)/18:2(n-6), and
20:3(n-6)/18:3(n-6) were calculated as indices of Δ5-desa-
turase, Δ6-desaturase, and elongase activity, respectively.
There were no differences between the arms at any time-
point, and no evidence suggesting longitudinal change
in enzyme activity during nutritional rehabilitation
(Additional file 1: Figure S2).
Baseline composition of LC-PUFA was an important
modulator of the compositional response to PUFA
provision. In the FFO-RUTF arm, children with low base-
line values of DHA had large increases, whilst amongst
those with relatively higher baseline DHA, enrichmentwas much less marked (Figure 3A). For those in both of the
non-fish oil arms, relatively low baseline DHA remained
constant; however, there was a marked decrease in DHA
amongst children who had higher levels at baseline. The re-
gression coefficients for the change in DHA by baseline
composition differed between the trial arms (P = 0.045
overall, and P = 0.025 between the S-RUTF and F-RUTF
arms; Figure 3B).
For EPA, the situation was different. Fish oil supplemen-
tation was associated with large increases in erythrocyte
EPA content regardless of baseline status, and for those in
the two non-fish oil arms, only those with relatively low
baseline EPA levels had any appreciable relative increase
during the study. The regression coefficients for the
change in EPA by baseline composition were significantly
different between arms (P = 0.018 overall, and P = 0.032
between FFO-RUTF and F-RUTF arms). The fact that in-
creases in EPA composition were largest in those children
in the fish oil group who had highest levels at baseline, im-
plies that provision of preformed EPA bypassed regulatory
mechanisms (Figure 3B).
Table 2 Compliance, safety, and growth
Compliance S-RUTF F-RUTF FFO-RUTF P
% RUTF to d28 89 (62 to 102) 95 (79 to 102) 95 (88 to 103) 0.42
% RUTF to d84 90 (80 to 101) 96 (67 to 100) 92 (76 to 100) 0.98
% Capsules to d28 – – 90 (71 to 99) –
% Capsules to d84 – – 88 (79 to 95) –
Safety
Deaths 1 3 2 0.86
Other serious adverse events 5 0 4 –
Total death or serious adverse event 6 3 6 0.63
Total illness episodes 50 47 54 0.27
Common illness syndromes
Upper respiratory tract infection 7 19 16 0.08
Lower respiratory tract infection 3 2 4 0.90
Rash 10 5 13 0.16
Diarrhea 7 7 4 0.75
Vomiting 2 6 7 0.20
Growth
Mid-upper arm circumference change
Enrolment to d28 (mm/day x103) 46 (21 to 72) 52 (24 to 68) 54 (36 to 75) 0.53
Enrolment to d84 (mm/day x103) 21 (17 to 39) 21 (17 to 29) 21 (18 to 29) 0.48
Weight-for-height/length change
Enrolment to d28 (z score/day x103) 57 (21 to 80) 60 (47 to 84) 58 (34 to 88) 0.23
Enrolment to d84 (z score/day x103) 20 (14 to 35) 21 (14 to 33) 23 (15 to 27) 0.96
Height/length-for-age change
Enrolment to d28 (z score/day x103) −11.9 (−22.9 to −2.5) −8.0 (−20.9 to −1.0) −10.4 (−15.7 to 2.9) 0.75
Enrolment to d84 (z score/day x103) 3.0 (−4.5 to 5.6) 4.0 (0.4 to 5.8) 0.2 (−2.3 to 4.6) 0.40
Head circumference-for-age change
Enrolment to d28 (z score/day x103) 10.1 (1.8 to 17.1) 13.2 (5.8 to 17.0) 6.1 (−6.4 to 20.4) 0.71
Enrolment to d84 (z score/day x103) 8.1 (0.6 to 9.8) 5.8 (3.9 to 8.4) 7.4 (1.2 to 9.3) 0.96
Data are absolute numbers or median (inter-quartile range) unless otherwise specified. Total illness episodes are compared by χ2 test. Individual illness syndromes,
deaths, and deaths/serious adverse events are by Fishers Exact test. Compliance and growth by ANOVA.
S-RUTF, Trial arm receiving standard-formulation RUTF without fish oil capsules; FFO-RUTF, Trial arm receiving flax seed oil-containing RUTF and fish oil capsules;
F-RUTF, Trial arm receiving flax seed oil-containing RUTF without fish oil capsules.
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Average changes in percentage composition of plasma
phosphatidylcholine PUFA were very similar to those seen
in the erythrocyte fraction, although plasma phosphatidyl-
choline was less enriched in PUFA overall and the observed
effect sizes were smaller (Additional file 1: Table S3). How-
ever, the relationships between participant-level erythrocyte
and plasma phosphatidylcholine data were highly variable
(Additional file 1: Figure S3 and Table S4).
T cells
Differences in the T cell compartment were less marked.
Modest relative increases in AA in the S-RUTF arm and
in EPA in the FFO-RUTF arm were evident in phosphat-
idylcholine species, but DHA was unaffected. There wasno effect of the intervention on phosphatidylethanolamine
species (where EPA was undetectable) (Additional file 1:
Table S5 and S6).
Growth
There were no detectable differences between the arms in
any of the growth indices measured (Table 2). There was
no difference in IGF-1 between the arms at any timepoint
but all arms had a highly significant increase in IGF-1 by
day 28 compared to baseline, which was sustained to day
84 (Additional file 1: Table S7).
Hematologic indices
Hemoglobin increased over the course of the trial in all
arms, and there were no differences between the arms in
Figure 2 Erythrocyte fatty acid composition. Median and interquartile ranges shown for the three arms at baseline, day 28, and day 84. Graphs
show (clockwise from top left) DHA, EPA, AA, n-6:n-3 ratio in LC-PUFA, and total LC-PUFA (n-6 and n-3). For between-arm comparisons (ANOVA) at
each time point: *P ≤0.05; **P ≤0.01; ***P ≤0.001. For within-arm comparison (sign test) to baseline values: † P ≤0.05. LC indicates species with carbon
chain >18.
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cell deformability) (Additional file 1: Figure S4). Marked
thrombocytosis developed over the early part of the study
in some participants. There was no clinical evidence of
coagulopathy in any participant at any point in the trial.
Inflammatory indices
There were no major differences in soluble inflammatory
markers in plasma between the arms at any time point
(Additional file 1: Table S7). There was a general reduc-
tion in levels of both pro- (e.g., IL-8, CXCL10) and anti-
inflammatory (e.g., IL-10) cytokines during the course of
the study. There were no differences in the proportion
of activated (CD38, HLA-DR co-expressing with/without
PD-1 expression) CD4 or CD8 T cells between groups at
day 84, though the proportion of PD-1 co-expressing
CD8 T cells had fallen in the S-RUTF and F-RUTF arms
(Additional file 1: Table S8). There was no significant
difference between the arms in IFN-γ release upon stimu-
lation with PHA with or without IL-12, or TT with IL-12,
at enrolment or day 84. Modest increases in IFN-γ releasein both of the PHA stimulation conditions were most pro-
nounced in the F-RUTF and FFO-RUTF arms. IFN-γ re-
lease induced by TT without IL-12 was undetectable in
cultures from most participants (Additional file 1: Table
S8). There were no significant associations between any of
the T cell functional parameters and corresponding T cell
LC-PUFA compositional indices.
Discussion
This study has shown that treatment of SAM with con-
ventional RUTF is associated with a decline in DHA
status. The production and administration of RUTF with
elevated n-3 PUFA (as ALA), with or without additional
fish oil as a supplement, to children with SAM is tech-
nically feasible, acceptable to patients and their carers,
and safe: the 10% mortality rate was in line with our and
others’ experience treating this extremely vulnerable
population with complicated SAM [22-25]. Provision of
RUTF with elevated ALA had minimal impact on n-6
and n-3 PUFA status, but addition of fish oil was associ-
ated with marked increases in n-3 LC-PUFA across
Figure 3 Effect modification of baseline PUFA status on EPA and DHA enrichment in erythrocytes. (A) Erythrocyte DHA and EPA between
both arms without fish oil (S-RUTF and F-RUTF) compared to FFO-RUTF. Participants are stratified on the basis of their baseline DHA or EPA values.
Low indicates equal to or below the median, and high indicates above the median. *P ≤0.05; **P ≤0.01; ***P ≤0.001 (by sign test). (B) Change in
erythrocyte DHA or EPA from baseline to day 84 plotted against baseline DHA or EPA. Regression lines are colored the same as corresponding group
symbols, black regression line is for S-RUTF and F-RUTF combined. P value is for effect modification across the three arms as described in the text.
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out fish oil, the percentage composition of DHA in
erythrocytes declined, suggesting an absolute require-
ment for preformed DHA in the nutritional manage-
ment of SAM.
An essential aim in the design of RUTF is to provide op-
timal nutrient intake for growth and development of som-
atic and neural tissues. RUTF compositional specifications
were based on infant formula guidelines, but in the period
since they were first developed a new consensus has
emerged that preformed LC-PUFA should be added to
infant formula in view of the fact that formula-fed in-
fants’ erythrocyte DHA declines without such exogenous
provision [26]. Dietary supply of DHA is considered con-
ditionally essential for infants and young children [13].
Our data have shown that similar declines occur during
nutritional rehabilitation of SAM using RUTF according
to current compositional guidelines. The impact of small
relative decreases in erythrocyte DHA content in this con-
text remains unclear. However, DHA is a major compo-
nent of neural lipid, and deficiency during early childhood
has been linked to a range of neurodevelopmental abnor-
malities [27]. Children with SAM are at risk of long-termcognitive and behavioral deficits [28], and it is plausible that
inadequate DHA provision during nutritional rehabilitation
could be an exacerbating factor. Because routinely provid-
ing preformed n-3 LC-PUFA to children with SAM may
have substantial resource and practical implications, policy
on formulation should be based on a clear assessment of
clinical (especially neurodevelopmental) utility, and trials
evaluating these outcomes should be prioritized. In 2011,
RUTF was provided to 1.96 million children, fewer than
10% of the many millions who needed it [29]. Concerns
around its composition should not detract from the clear
current imperative to support and expand coverage.
ALA can theoretically act as a substrate for biosynthesis
of all the longer chain n-3 PUFA family members, but par-
ticipants in the F-RUTF arm, who received far more ALA
than those in the S-RUTF arm, had relatively modest
changes in n-3 LC-PUFA after three months’ treatment.
Point estimates for percentage content of EPA and doco-
sopentaenoic acid (DPA, 22:5(n-3)) were increased, but
the failure to impact positively on DHA was notable. The
results bear comparison to previous clinical studies, which
have suggested that while provision of ALA can be shown
to drive increases in EPA and DPA content, metabolic
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supply of preformed DHA is conditionally essential for its
tissue enrichment [30-32]. Recent experimental work sug-
gests that provision of large quantities of dietary ALA
might inadvertently further limit its already slow metabol-
ism to DHA. By systematically varying LA and ALA intake
in rats, Gibson et al. found that increasing ALA above an
optimal concentration was independently associated with a
decrease in tissue DHA accumulation due to competitive
inhibition of a part of the conversion step from DPA to
DHA catalyzed by Δ6 desaturase [33]. Similar inhibition
may occur by competition for elongase enzyme activity
[34]. It is therefore possible that although by providing ele-
vated ALA content we increased the available substrate for
DHA biosynthesis, ALA may have inhibited those same
metabolic pathways to which it is subject, rendering the
supplementation futile as regards DHA accretion. Al-
though it is reassuring that children in the arm receiving
elevated ALA without fish oil did not see a decrease in
DHA levels beyond that seen with the standard RUTF for-
mulation, this theoretical concern means that we do not
believe that RUTF formulations with high ALA content
should be taken forward to further clinical trials. Further-
more, although desaturase and elongase activity was simi-
lar between the arms, the fact that AA differed after three
months’ follow-up is difficult to explain by any means
other than an ALA-dependent decrease in LA conversion
to AA. This alone might have had important conse-
quences, since AA status has been related to growth [35].
An alternative strategy to improve DHA accretion dur-
ing nutritional rehabilitation may be to reduce the n-6
PUFA content of RUTF, because it is well recognized that
n-6 PUFA can interfere with desaturation and elongation
of ALA [36]. An attractive feature of such an approach is
the possible avoidance of problems associated with stabil-
ity during storage for products with increased PUFA con-
tent. Although we believe that the high drop-out rate in
the F-RUTF arm is likely to be random statistical noise
(it did not occur in FFO-RUTF arm, who also received the
flax seed oil-containing product), the fact that the flax
seed oil-containing RUTF became unusable after just a
year despite packaging under nitrogen and storage below
25°C presents a major practical impediment to its use in
countries or areas with limited resources. There are prece-
dents for n-6 PUFA reduction as a means of increasing
n-3 LC-PUFA biosynthesis, although the effectiveness in
terms of DHA accumulation in clinical studies has been
modest to date [37-39]. An important consideration will be
to ensure that n-6 LC-PUFA status itself is not compro-
mised, since this may have adverse consequences for
growth, as noted previously [35]. Notwithstanding these
concerns, a major part of the reason that RUTF have been
successful is that it is straightforward to administer, and the
development of a formulation that could address DHAaccretion without resorting to provision of encapsulated
fish oil should be the eventual aim. In pilot work (unpub-
lished), we attempted to synthesize an RUTF containing
fish oil as part of the RUTF mix, but it quickly became ran-
cid. There is considerable interest in the production of n-3
LC-PUFA-based products that are resistant to environmen-
tal oxidation, but achieving durable stability as part of a
mix with highly oxidizing micronutrients, such as iron, will
be a major challenge. On the other hand, a recent paper
describing the results of a clinical trial of using RUTF with
different PUFA compositions in the treatment of SAM in
Malawi, has suggested that even higher doses of ALA than
we employed might have benefit [40]. In this study, treat-
ment with an RUTF with very-high LA (21.3% of total fatty
acids) and low ALA (0.4%) was associated with a decrease
in DHA content of plasma phospholipids after four weeks,
but a modified product with lower LA content (although,
at 13.1%, still similar to Plumpy’nut) and high ALA (13.1%)
protected against this decline. There was no evidence of a
detrimental impact on growth or recovery from SAM; in
fact, children in the modified RUTF arm experienced a
greater improvement in weight-for-height than those in the
standard arm, although the high prevalence of kwashiorkor
at baseline means that this result is difficult to interpret.
The modified formulation contained ALA at more than
twice the level in our flax seed oil-enriched formulation.
Our experience suggests that achieving long-term stability
of a preparation with such high ALA content may be diffi-
cult, but if stability could be achieved, then this formulation
might minimize DHA depletion whilst maintaining the
practicality of an exclusively RUTF-based regime.
Although there is no precise cutoff for defining DHA
deficiency, Luxwolda et al. demonstrated that transplacen-
tal materno-fetal transfer of DHA is actively regulated to-
wards providing infants with 5.9% DHA composition in
erythrocytes at birth, and it is hypothesized that DHA
composition of around 7% is optimal for prevention of
some non-communicable diseases in adulthood [41-43].
By comparison, children enrolled in this study had mar-
ginally low baseline DHA (median (interquartile range),
5.2% (3.7–6.7)), but regulated their erythrocyte compos-
ition at around 7% in the presence of preformed DHA in
the diet. Several previous studies have investigated fatty
acid status in malnourished children, and while analyses
of erythrocyte and plasma lipids have proved highly incon-
sistent, relatively low levels of AA and DHA are most
frequently reported [44-51]. Composition of plasma and
erythrocytes should only be regarded as proxy measures
of sufficiency, since it is possible that preservation of their
composition is achieved by diversion away from other tis-
sue compartments. There is little doubt that children with
SAM are at high risk for having very low recent n-3
LC-PUFA intake. For young children, the major dietary
source of n-3 and n-6 PUFA is breast milk, the composition
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systematic review of studies measuring breast milk com-
position revealed that breast milk from sub-Saharan African
mothers has consistently high AA content but very variable
DHA content, probably driven by large local discrepancies
in access to fish [53]. Access to dietary sources of fish and
n-3 PUFA is strongly related to GDP on a per-country basis
[54], and a detailed analysis of fatty acid intake by Gambian
children revealed a steep decline in n-3 PUFA and pre-
formed LC-PUFA at the point of weaning [55]. In condi-
tions of moderate or intermittent food insecurity far from
sources of affordable fish (where intake of n-3 LC-PUFA is
likely to be marginal) it is reasonable to assume that re-
duced food security would be associated with reduced fish
intake for both breastfeeding mothers and their children in
many circumstances.
While DHA content appeared to be regulated, EPA did
not – the greatest increases in erythrocyte EPA with fish
oil provision being among those participants with the high-
est baseline values (Figure 3B). Percentage EPA compos-
ition reached levels equivalent to those seen in populations
that consume very large amounts of marine fish [56]. It is
plausible that providing preformed EPA (but not, appar-
ently, DHA) bypasses a physiologically beneficial regulatory
checkpoint, and detailed assessment of safety outcomes
should form an important component of future studies
if oils containing high levels of EPA, as used here, are
employed. We deliberately chose to use fish oil with
high EPA content because we hypothesized that its anti-
inflammatory properties might be beneficial in the context
of SAM. The lack of any measurable impact on inflamma-
tion in this study further discourages the use of such oils
in future work. Understanding the kinetics of EPA accu-
mulation would be helped by fatty acid desaturase gene
cluster profiling, given that common polymorphisms
could have a substantial impact on PUFA metabolic re-
sponses to supplementation [57]. This should be con-
sidered as a component of further research.
This study builds on previous work in different settings.
Smit et al. randomized 17 Pakistani children with low
weight-for-age z-score to 500 mg/day of fish oil alongside
standard care (n = 10), which consisted of multivitamin
provision and parental nutritional education, or standard
care alone for up to 12 weeks [58]. They demonstrated a
marked increase in erythrocyte composition of all n-3 LC-
PUFA in the intervention arm but no change from base-
line in the controls. Koletzko et al. demonstrated an in-
crease in n-3 LC-PUFA in plasma phospholipids from
baseline in a cohort of 8 Nigerian children with SAM after
two weeks of follow-up when provided a rehabilitation
diet that contained fish [45]. In a recent controlled trial of
fish oil supplementation for young infants without SAM
in the Gambia, van der Merwe et al. effected increases in
plasma n-3 LC-PUFA and in MUAC in the interventiongroup [59]. There was no difference in intestinal health,
frequency of illness, or neurocognitive development, but
breastfeeding rates were high in the trial and the mothers’
breast milk was unusually rich in DHA, meaning that the
participants were much more likely to be n-3 LC-PUFA
replete than those in our study.
n-6 and n-3 LC-PUFA and their metabolites are po-
tent immunomodulatory agents, with n-6 PUFA family
members being broadly pro-inflammatory and n-3, anti-
inflammatory [9]. Children with SAM have a chronic in-
flammatory T cell-associated enteropathy (environmental
enteric dysfunction), which may be partly maladaptive and
disrupt beneficial effects of nutritional rehabilitation [60].
Provision of RUTF with a high n-6 PUFA content could
exacerbate this inflammatory activation, thereby further
disturbing mucosal homeostasis and contributing to wors-
ening of gastrointestinal symptoms, increase in microbial
translocation, and persistent growth failure. However, al-
though we demonstrated major differences in n-3 PUFA
composition between the three arms in multiple compart-
ments, there was no evidence of consistent or major impact
on any of the numerous immunologic and inflammatory
indices measured in exploratory analyses. Hospitalized chil-
dren with SAM are an extremely heterogeneous group.
Some have or are recovering from a major infection, others
have chronic illnesses, and some present early without
major medical or metabolic complications, but require
a short period of hospital care because of inadequate facil-
ities for care at home. A wide range of inflammatory and
immunologic status would therefore be expected at base-
line and the impossibility of controlling or correcting for
this in a small trial render the likelihood of a type 2 error
high. Additionally, while understanding of the importance
of PUFA in immune function is informed by a wealth of
data from model and experimental settings encompassing
a wide range of methodological approaches, our cellular
and molecular understanding of the functionally immuno-
compromised state associated with SAM is extremely lim-
ited [4,9]. Our choice of assays was hypothesis-based but
evidence underlying these hypotheses is weak. Further
careful observational work to determine the relationship
between enteric inflammation, mucosal and systemic im-
mune function, and nutritional status is a research priority,
and the utilization of exploratory and systems biological ap-
proaches are likely to be useful in challenging established
models.
Conclusions
PUFA requirements of children with SAM are not met by
RUTF manufactured according to current specifications,
and are associated with a drop in DHA during nutritional
rehabiliation. Although this trial was well powered to as-
sess for compositional indices as primary outcome, it was
not designed or powered to assess for clinically important
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fectious episodes. The safety and acceptability of the ap-
proach employed provides a sound foundation for future
trials targeting such outcomes on a much larger scale.
That our RUTF formulation with elevated ALA content
did not enrich for DHA and quickly became unusable,
suggests that simply increasing the stipulated ALA con-
tent of RUTF is not a sufficient adaptation to current stan-
dards, and such a formulation is not a rational one to take
forward for larger-scale trials. Low n-6 PUFA content for-
mulations are potential candidates, but for trials designed
to show proof of concept that raising n-3 LC-PUFA has
clinical and growth benefits, providing the preformed
molecules themselves may provide the clearest, quickest,
and most unambiguous answer.
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